The U.S. Food & Drug Administration (FDA) has approved Biogen Inc.’s nusinersen drug for treating children and adults suffering form the spinal muscular atrophy (SMA) genetic disease.

Biogen Idec and partner Swedish Orphan Biovitrum AB promised donations of hemophilia drugs for use in developing nations, in a bid to make it possible for thousands of patients to receive the much-needed treatment over the next decade.

The announcement was made during the World Federation of Hemophilia (WFH) meeting in Melbourne, Australia, on Monday.